Clinical Trial Goal
To find out:
- The highest dose of ARV-393 that's safe to give
- If ARV-393 is safe and works well to treat NHL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have B-cell NHL that has relapsed or is refractory. Some examples include:
- Burkitt lymphoma
- Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL)
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Lymphoblastic lymphoma
- Mantle cell lymphoma (MCL)
- Marginal zone lymphoma (MZL)
- Primary Mediastinal large B-cell lymphoma (PMBCL)
- Waldenström macroglobulinemia
- Have not had an autologous (your own cells) or allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 3 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
ARV-393 is a B-cell lymphoma 6 (BCL6) protein degrader.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- ARV-393 – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved ARV-393.
Locations
Sponsors
lead: Arvinas Inc.
